X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · Real-Time Price · USD
0.2217
-0.0147 (-6.22%)
At close: Apr 1, 2025, 4:00 PM
0.2210
-0.0007 (-0.32%)
After-hours: Apr 1, 2025, 4:36 PM EDT
X4 Pharmaceuticals Revenue
In the year 2024, X4 Pharmaceuticals had annual revenue of $2.56M. X4 Pharmaceuticals had revenue of $1.43M in the quarter ending December 31, 2024.
Revenue (ttm)
$2.56M
Revenue Growth
n/a
P/S Ratio
18.59
Revenue / Employee
$17,881
Employees
143
Market Cap
38.50M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
XFOR News
- 7 days ago - X4 Pharmaceuticals, Inc. (XFOR) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 7 days ago - X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 21 days ago - X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025 - GlobeNewsWire
- 5 weeks ago - X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries - GlobeNewsWire
- 7 weeks ago - X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia - GlobeNewsWire
- 2 months ago - X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome - GlobeNewsWire
- 2 months ago - X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand - GlobeNewsWire